Latest News and Press Releases

WATERTOWN, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

XERAVATM (eravacycline) Now Available to Hospitals in the United States Conference Call Today at 4:30 p.m. Eastern Time WATERTOWN, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Tetraphase...

WATERTOWN, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

WATERTOWN, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

FDA-Approved for the Treatment of Complicated Intra-Abdominal Infections Provides Broad Spectrum of Coverage Against Gram-negative, Gram-positive, and Anaerobic Bacteria for a Range of Patients with...

XERAVA Demonstrated Efficacy in Treating Secondary Bacteremia in Patients with Complicated Intra-Abdominal Infections in Post-Hoc Analysis of Phase 3 Clinical Trials TP-6076 Demonstrated...

WATERTOWN, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

WATERTOWN, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) --...